Keywords
depressive disorders
antidepressant drugs
monoamine theory of depression
Abstract
Depression is one of the greatest current mental disorders. Depressive disorder may affect everyone and it causes difficulties in social functioning and may lead to death via suicide. Depression is a serious problem because number of its cases is increasing, especially after pandemic of COVID-19. The oldest and the most approved theory which explains mechanism of depression’s development is a monoamine hypothesis. Effectiveness of most antidepressant drugs based on this theory. It assumes that the typical symptoms of depression are results of changed concentration of monoamines or incorrect monoaminergic transmission. The aim of this article is to present drugs which have influence on level of biogenic amines and are used in treatment of depressive disorders. Some of those drugs are the first choice in cure of this disease. In spite of adverse effects and often delayed onset of action of pharmacotherapy, it is still the first line in treatment of depression.References
1. WHO; 2023. [https://www.who.int/news-room/fact-sheets/detail/depression]
2. WHO; 2023. [https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide]
3. Jesulola E, Micalos P, Baguley IJ. Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model – are we there yet? Behav Brain Res. 2018;34:79-90.
4. Albert PR. Why is depression more prevalent in women? J Psychiatry Neurosci. 2015;40(4):219-21.
5. Guo P, Chen S, Wang H, Wang Y, Wang J. A systematic analysis on the genes and their interaction underlying the comorbidity of Alzheimer’s disease and major depressive disorder. Front Aging Neurosci. 2022;13:1-17.
6. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Association; 2013:155,181.
7. Dudek D, Siwek M. Współistnienie chorób somatycznych i depresji. Via Medica. 2007;4(1):17-24.
8. Perez-Caballero L, Torres-Sanchez S, Romero-López-Alberca C. et al. Monoaminergic system and depression. Cell Tissue Res. 2019;377:107-13.
9. Jiang Y, Zou D, Li Y, Gu S, Dong J, Ma X, et al. Monoamine neurotransmitters control basic emotions and affect major depressive disorders. Pharmaceuticals (Basel).2022;15(10):1203.
10. Ślifirski G, Król M, Turło J. 5-HT Receptors and the development of new antidepressants. Int J Mol Sci. 2021;22(16):9015.
11. Pandarakalam JP. Challenges of treatment-resistant depression. Psychiatr Danub. 2018;30(3):273-84.
12. Sabella D. Antidepressant medications. Am J Med. 2018;118(9):52-9.
13. Fritze, S, Spanagel, R, Noori, HR. Adaptive dynamics of the 5-HT systems following chronic administration of selective serotonin reuptake inhibitors: a meta-analysis. J Neurochem. 2017;142:747-55.
14. Drugbank. [https://go.drugbank.com/]
15. Schwasinger-Schmidt TE, Macaluso M. Other Antidepressants. Handb Exp Pharmacol. 2018;250:325-55.
16. Miller JJ. Rx evolution: An ununified model of MDD and pharmacological paradigms. Psychiatr Times. 2023;40(2):1-7
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2023 Authors